Carmela Gómez

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Spinal Cord Injury

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Pablo V Escribá, Ángel M Gil-Agudo, Joan Vidal Samsó, Judith Sánchez-Raya, Sebastián Salvador-de la Barrera, Vanesa Soto-León, Natacha León-Álvarez, Bosco Méndez Ferrer, Miguel David Membrilla-Mesa, Carolina Redondo Galán, Jesús Benito-Penalva, Antonio Montoto-Marqués, Javier Medel Rebollo, Ramiro Palazón García, Francisco Gutiérrez Henares, Marc Miralles, Manuel Torres, Ana Belén Nieto-Librero, David García Marco, Carmela Gómez, David Jimeno, Antonio Oliviero
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury. Spinal cord 62 (8) (2024)
Pablo V Escribá, Ángel M Gil-Agudo, Joan Vidal Samsó, Judith Sánchez-Raya, Sebastián Salvador-de la Barrera, Vanesa Soto-León, Natacha León-Álvarez, Bosco Méndez Ferrer, Miguel David Membrilla-Mesa, Carolina Redondo Galán, Jesús Benito-Penalva, Antonio Montoto-Marqués, Javier Medel Rebollo, Ramiro Palazón García, Francisco Gutiérrez Henares, Marc Miralles, Manuel Torres, Ana Belén Nieto-Librero, David García Marco, Carmela Gómez, David Jimeno, Antonio Oliviero
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury. Spinal cord 62 (8) (2024)
Pablo V Escribá, Ángel M Gil-Agudo, Joan Vidal Samsó, Judith Sánchez-Raya, Sebastián Salvador-de la Barrera, Vanesa Soto-León, Natacha León-Álvarez, Bosco Méndez Ferrer, Miguel David Membrilla-Mesa, Carolina Redondo Galán, Jesús Benito-Penalva, Antonio Montoto-Marqués, Javier Medel Rebollo, Ramiro Palazón García, Francisco Gutiérrez Henares, Marc Miralles, Manuel Torres, Ana Belén Nieto-Librero, David García Marco, Carmela Gómez, David Jimeno, Antonio Oliviero
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury. Spinal cord (2024)
Pablo V Escribá, Ángel M Gil-Agudo, Joan Vidal Samsó, Judith Sánchez-Raya, Sebastián Salvador-de la Barrera, Vanesa Soto-León, Natacha León-Álvarez, Bosco Méndez Ferrer, Miguel David Membrilla-Mesa, Carolina Redondo Galán, Jesús Benito-Penalva, Antonio Montoto-Marqués, Javier Medel Rebollo, Ramiro Palazón García, Francisco Gutiérrez Henares, Marc Miralles, Manuel Torres, Ana Belén Nieto-Librero, David García Marco, Carmela Gómez, David Jimeno, Antonio Oliviero
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury. Spinal cord 62 (8) (2024)